Lung Cancer Protocols

ALCHEMIST A151216: (NCT# 02194738) Stage IB-IIIA Non-small cell lung cancer

that has been removed. Tissue submission from the specimen already taken for testing. EGFR and ALK genotyping will be performed. If they both return negative it will be sent for one more test, PD-L1. These tests may make you eligible for some other type of treatment or eligible for one of our clinical trials, see below:

ALCHEMIST A081801: (NCT# 04267848) If you test negative for ALK and EGFR and have not had any therapy, you may be eligible for this trial.

The study is for chemotherapy: platinum doublet therapy (Your doctors’ choice) with or without immunotherapy Keytruda (pembrolizumab).

ALCHEMIST E4512: (NCT# 02201992) If you are ALK positive and have not had therapy, you may be eligible for this trial. You would either receive immunotherapy Xalkori (crizotinib) or observation only.

DS1062-A-U301: (NCT# 04656652) Advanced or metastatic non-small cell lung cancer that is negative for EGFR, and ALK testing. (stage IIIB, IIIC, IV).  

Requires that you already received chemotherapy and then progressed.

You would receive chemotherapy, either DS-1062a or docetaxel

If you would like more details about each trial, you can find them on https://clinicaltrials.gov/ and use the NCT number supplied for each trial.

Frances Dallesandro                                                               Kara Potter, BSN, RN

Protocol Office Manager                       Fax Number                 Research Nurse

(401)456-2698                                    (401)456-2658              (401)456-2567